ArticleClinical pharmacology and therapeutics2025
Drug-Event Pairs as Indicators for the Detection of Adverse Drug Reactions during Hospitalization in Routinely Collected Electronic Data Sources.
Article in Clinical pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Intelligent Framework for Adverse Drug Event Identification Using Large Language Models and Retrieval-Augmented Generation: Development and Evaluation Study.Journal of medical Internet research · 2026Article
- Development and analysis of a SmPC-based machine-readable dataset of contraindications for clinical decision support and real-world data analysis.European journal of clinical pharmacology · 2026Article
- Development of phenotype algorithms for the detection of adverse events in electronic health record data: a multicentre study.BMJ open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse drug reactions (ADRs) are a common cause of morbidity and mortality in hospitalized patients. Identification of ADRs in clinical practice, surveillance and research is essential to prevent further harm. The aim of this study was to assess the likelihood of drugs contributing to clinically important inpatient adverse events, in order to provide a list of drug-event pairs indicating ADRs in electronic health record (EHR) data, referred to as "indicators of ADRs". We conducted a consensus process based on the RAND/UCLA Appropriateness Method for 14 ADRs. Experts were asked to rate the strength of the causal link between adverse events and potentially causative drugs on a 4-point Likert scale. Based on the median rating, drug-event pairs were categorized according to the likelihood of an ADR being present. Drug-event pairs with a median rating of ≥ 3 without disagreement were defined as indicators of certain and probable ADRs. Of the 255 drug-event pairs evaluated, 2 (1%) and 42 (16%) achieved consensus validation that they certainly and probably indicate an ADR. In addition, 137 drug-event pairs were considered as indicators of possible (54%) and 74 drug-event pairs were considered as indicators of unlikely (29%) ADRs. The provided set of content-validated indicators of clinically important inpatient ADRs can be used in clinical practice (e.g., decision support), surveillance (e.g., quality indicators) and research (e.g., outcome measures). They will be implemented in EHR data from German university hospitals to determine the prevalence of ADRs, support efficient use of pharmacist resources, and develop models predicting ADRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.